Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486381 | 1.00 | LOXL2 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488027 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488414 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488024 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL30457900 | 0.77 | TAS1R3 (0.50) | LOXL2AGXTPSMB5PSMB8TAS1R3 | |
| SCHEMBL4436085 | 0.76 | CYP2D6 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL4340930 | 0.76 | CYP2D6 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL19550896 | 0.74 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL30458044 | 0.74 | SIGMAR1 (0.49) | LOXL2CYP2D6HIF1AMAOBSIGMAR1 | |
| SCHEMBL30457823 | 0.74 | SIGMAR1 (0.49) | LOXL2CYP2D6HIF1AMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087984-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | FUJIMOTO CO LTD (JP) | 2021-04-07 | — | — | EP | claimed |
| EP-3226852-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | claimed |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | claimed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | claimed |
| US-9782383-B2 | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder | FUJIMOTO CO., LTD. (JP) | 2017-10-10 | — | — | US | claimed |
| EP-3087984-A1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Fujimoto Co., Ltd. (JP) | 2016-11-02 | — | — | EP | claimed |
| US-20160296495-A1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | FUJIMOTO CO., LTD. (JP) | 2016-10-13 | — | — | US | claimed |
| EP-2158908-B1 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION | FUJIMOTO CO LTD (JP) | 2013-04-24 | — | — | EP | claimed |
| US-20130005800-A1 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION | YONEDA FUMIO (JP) | 2013-01-03 | — | — | US | claimed |
| US-8318799-B2 | Therapeutic agent for substance dependence | NATIONAL UNIVERSITY CORPORATION KYUSHU UNIVERSITY (JP) | 2012-11-27 | — | — | US | claimed |
| EP-2158908-A1 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION | Fujimoto Co., Ltd. (JP) | 2010-03-03 | — | — | EP | claimed |
| EP-1815853-B1 | THERAPEUTIC AGENT ((-)-BPAP) FOR DRUG DEPENDENCE | UNIV KYUSHU NAT UNIV CORP (JP) | 2009-04-22 | — | — | EP | claimed |
| US-20080004337-A1 | Therapeutic Agent for Substance Dependence | FUJIMOTO CO., LTD. (JP) | 2008-01-03 | — | — | US | claimed |
| EP-1815853-A1 | THERAPEUTIC AGENT FOR DRUG DEPENDENCE | Kyushu University, National University Corporation (JP) | 2007-08-08 | — | — | EP | claimed |
| EP-1052259-B1 | NOVEL OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE | FUJIMOTO BROTHERS CO LTD (JP) | 2007-04-18 | — | — | EP | claimed |
| EP-0957080-B1 | NOVEL ETHYLAMINE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-06-21 | — | — | EP | claimed |
| US-6391914-B1 | NEUROTRANSMITTERS; PSYCHOLOGICAL DISORDERS, ANTIDEPRESSANTS;THERAPY FOR PARKINSON'S AND ALZHEIMER'S DISEASE | FUJIMOTO BROTHERS CO., LTD. (JP) | 2002-05-21 | — | — | US | claimed |
| US-6214859-B1 | PSYCHOLOGICAL DISORDERS; ALZHEIMER'S DISORDERS; PARKINSON'SDISORDERS | FUJIMOTO BROTHERS CO., LTD. (JP) | 2001-04-10 | — | — | US | claimed |
| EP-1052259-A1 | NOVEL OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE | Fujimoto Brothers Co., Ltd. (JP) | 2000-11-15 | — | — | EP | claimed |
| EP-0957080-A1 | NOVEL ETHYLAMINE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 1999-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004337-A1 | Therapeutic Agent for Substance Dependence | OPRM1, GABARAP, OPRK1 | LOXL2 2155/4885CYP2D6 1404/4885HIF1A 889/4885 |
| US-20130005800-A1 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION | APP, GAP43, PSEN1 | LOXL2 3215/4885CYP2D6 45/4885HIF1A 4337/4885 |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | TMSB10, PNMT, HNMT | LOXL2 4402/4885CYP2D6 3599/4885HIF1A 692/4885 |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | TMSB10, PNMT, HNMT | LOXL2 4454/4885CYP2D6 3495/4885HIF1A 646/4885 |
| US-20160296495-A1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SLC6A2, SLC6A3, SLC6A4 | LOXL2 4400/4885CYP2D6 893/4885HIF1A 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.